REFERENCES
1. Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, et al. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975;50:621-37.
2. Rotta FT, Sussman AT, Bradley WG, Ram Ayyar D, Sharma KR, et al. The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2000;173:129-39.
3. Bunschoten C, Jacobs BC, Van den Bergh PYK, Cornblath DR, van Doorn PA. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol 2019;18:784-94.
4. Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001;24:311-24.
5. European federation of neurological societies/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European federation of neurological societies and the periphe. J Peripher Nerv Syst 2010;15:1-9.
6. Karri M, Ramasamy B. Isolated unilateral palatal and vocal cord palsy as an initial presentation of chronic inflammatory demyelinating polyradiculoneuropathy. Egypt J Neurol Psychiatr Neurosurg 2019;55:79.
7. Bhatt NK, Pipkorn P, Paniello RC. Association between upper respiratory infection and idiopathic unilateral vocal fold paralysis. Ann Otol Rhinol Laryngol 2018;127:667-71.
8. Hughes RAC, Donofrio P, Bril V, Dalakas MC, Deng C, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008;7:136-44.
9. Teramoto H, Morita A, Hara M, Ninomiya S, Shigihara S, et al. Relapse with dysphagia in a case of chronic inflammatory demyelinating polyradiculoneuropathy. Intern Med 2015;54:1791-3.
10. Lux D, Zarkali A, Harikrishnan S. Cranial neuropathy in chronic inflammatory demyelinating polyradiculoneuropathy: a consideration with variable response to treatment. J Neurol Sci 2017;381:781.
11. Berger M, McCallus DE, Lin CSY. Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies. J Peripher Nerv Syst 2013;18:275-96.
12. Mielke O, Bril V, Cornblath DR, Lawo JP, van Geloven N, et al. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: results from the pre-randomization phase of the polyneuropathy and treatment with hizentra study. J Peripher Nerv Syst 2019;24:72-9.
